The technology was discovered and patented by the Pharmaceutical Research Institute of Warsaw, Poland and involves compounds that appear to be novel antimicrotubule agents.
Donald Picker, COO of Edgeline Holdings, said: “We are very excited to have the opportunity to develop what may be yet another unique antimicrotubule class of compounds. This specific mechanism continues to be of great interest to the cancer research community as it may provide yet another different spectrum of activity in the clinic.”